Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second phase III trial of forigerimod for systemic lupus erythematosus.

Trial Profile

Second phase III trial of forigerimod for systemic lupus erythematosus.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Forigerimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 30 Apr 2015 According to ImmuPharma media release, agreement was signed with Simbec-Orion an international clinical research organisation to under take crucial Phase III clinical trial.
    • 13 Aug 2013 New trial record
    • 12 Aug 2013 This is one of two trials in the phase III programme, according to an ImmuPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top